PMID- 35255819
OWN - NLM
STAT- MEDLINE
DCOM- 20220309
LR  - 20221207
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 22
IP  - 1
DP  - 2022 Mar 7
TI  - Investigating the effect of quadruple therapy with Saccharomyces boulardii or 
      Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of 
      Helicobacter pylori and treatments adverse effects: a double-blind 
      placebo-controlled randomized clinical trial.
PG  - 107
LID - 10.1186/s12876-022-02187-z [doi]
LID - 107
AB  - BACKGROUND: The goal of this study was to investigate the effects of treatment 
      with Saccharomyces boulardii and Lactobacillus reuteri on the eradication of 
      Helicobacter pylori and Adverse effects (AEs) of the treatment. RESULTS: This 
      study was a double-blind, randomized, placebo-controlled trial. And, eradication 
      of H. pylori was reported comparing quadruple therapy include of PPI (proton pomp 
      inhibitor), bismuth subcitrate, clarithromycin, and amoxicillin versus quadruple 
      therapy supplemented with S. boulardii and L. reuteri DSMZ 17648. For this aim, a 
      total of 156 patients were included in the current study; and patients positive 
      for H. pylori infection (n = 156) were randomly assigned to 3 groups: 52 patients 
      (Group P) received conventional quadruple therapy plus L. reuteri, 52 patients 
      (Group S) received conventional quadruple therapy plus S. boulardii daily, for 
      2 weeks, and 52 patients were in the control group (Group C). At the end of the 
      treatment period, all the subjects continued to take proton pump inhibitor (PPI) 
      alone for 14 days, and then, no medication was given for 2 weeks again. During 
      follow-up, gastrointestinal symptoms were assessed using an evaluation scale 
      (Glasgow dyspepsia questionnaire [GDQ]), and AEs were assessed at 7, 14, 21, and 
      28 days. As a result, all patients completed the treatment protocol in all groups 
      by the end of the study. Additionally, eradication therapy was effective for 
      94.2% of subjects in Group S, 92.3% of subjects in Group P, and 86.5% of subjects 
      in the control group, with no differences between treatment arms. In Group S, the 
      chance of developing symptoms of nausea (OR = 2.74), diarrhea (OR = 3.01), 
      headache (OR = 10.51), abdominal pain (OR = 3.21), and anxiety (OR = 3.58) was 
      significantly lower than in the control group (p < 0.05). CONCLUSION: S. 
      boulardii could significantly reduce some AEs of H. pylori eradication therapy, 
      but effectiveness of Lactobacillus reuteri on these cases was not significant. It 
      is recommended to conduct the future research with larger sample size in order to 
      investigate the effect. TRIAL REGISTRATION: IRCT20200106046021N1, this trial was 
      registered on Jan 14, 2020.
CI  - (c) 2022. The Author(s).
FAU - Naghibzadeh, Nooshin
AU  - Naghibzadeh N
AD  - Gastroenterology Department, Faculty of Medicine, Birjand University of Medical 
      Science, Birjand, Iran.
FAU - Salmani, Fatemeh
AU  - Salmani F
AD  - Epidemiology and Biostatistics Department, Social Determinants of Health Research 
      Center, Faculty of Health, Birjand University of Medical Sciences, Birjand, Iran.
FAU - Nomiri, Samira
AU  - Nomiri S
AD  - Clinical Biochemistry Department, Faculty of Medicine, Birjand University of 
      Medical Sciences, Birjand, Iran.
FAU - Tavakoli, Tahmine
AU  - Tavakoli T
AD  - Gastroenterology Department, Faculty of Medicine, Birjand University of Medical 
      Science, Birjand, Iran. tahminetavakoli95238@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220307
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 804826J2HU (Amoxicillin)
SB  - IM
MH  - Amoxicillin/adverse effects
MH  - Anti-Bacterial Agents/adverse effects
MH  - Drug Therapy, Combination
MH  - *Helicobacter Infections/drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - *Limosilactobacillus reuteri
MH  - Proton Pump Inhibitors/adverse effects
MH  - *Saccharomyces boulardii
MH  - Treatment Outcome
PMC - PMC8903632
OTO - NOTNLM
OT  - Adverse effects
OT  - Eradication rate
OT  - Helicobacter pylori
OT  - Lactobacillus reuteri
OT  - Saccharomyces boulardii
OT  - Sequential treatment
COIS- The authors declare that they have no competing interests.
EDAT- 2022/03/09 06:00
MHDA- 2022/03/11 06:00
PMCR- 2022/03/07
CRDT- 2022/03/08 05:33
PHST- 2021/09/16 00:00 [received]
PHST- 2022/02/28 00:00 [accepted]
PHST- 2022/03/08 05:33 [entrez]
PHST- 2022/03/09 06:00 [pubmed]
PHST- 2022/03/11 06:00 [medline]
PHST- 2022/03/07 00:00 [pmc-release]
AID - 10.1186/s12876-022-02187-z [pii]
AID - 2187 [pii]
AID - 10.1186/s12876-022-02187-z [doi]
PST - epublish
SO  - BMC Gastroenterol. 2022 Mar 7;22(1):107. doi: 10.1186/s12876-022-02187-z.